Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events

In the SHASTA-3/4 clinical trials, a remarkable efficacy was demonstrated with a 79-81% reduction in triglycerides and a 78% reduction in pancreatitis events. The submission of a supplemental New Drug Application (sNDA) is planned for the end of 2026, and the acquisition of a Priority Review Voucher (PRV) significantly increases commercialization visibility for 2027. Although cash consumption will continue until the point of revenue generation, the resolution of technical success risks is expected to enhance partnership and licensing negotiation power.

The current price of 89.59 has a potential upside of 6.6% to the resistance level of 95.49, while there is a 22% downside risk to the support level of 69.88, indicating an asymmetric risk profile. The RSI at 71.9 suggests that the stock is in the overbought range, and the increase in low trading volume indicates the possibility of a short-term pullback.

The successful topline results of the Phase III trial for its own pipeline product plozasiran and the plan to submit a supplemental New Drug Application (sNDA) within the year, along with the acquisition of a Priority Review Voucher (PRV), are key momentum for the reevaluation of corporate value. However, despite a +5.4% increase on the day of the news announcement, trading volume was only 0.54 times the 20-day average, making it difficult to confirm institutional buying interest — indicating a strong short-term news play nature.